Monday, July 23, 2018

Sangamo Therapeutics Acquires TxCell

Richmond, California-based Sangamo Therapeutics, which is developing gene therapy, genome editing, gene regulation, and other technology, has acquired French company TxCell, Sangamo announced onMonday. Sangamo will pay approximately $84M for TxCell. TxCell is working on products related to regulatory T cell (Treg) development for immunological diseases, including Crohn's disease and multiple sclerosis.